Merck KGaA (DE:MRK)
XETRA:MRK
Top Page
Merck KGaA
(XETRA:MRK)
Select Model
Select Model
Rating:58Neutral
Price Target:
€115.00
▲(1.77% Upside)
Action:DowngradedDate:03/07/26
The score is led by solid underlying profitability and a sound balance sheet, but it is pulled down by a pronounced bearish technical setup (price below key moving averages and negative MACD). Valuation is moderate with a ~2% yield, offering some support but not enough to offset weakening recent growth and momentum.
Positive Factors
Diversified business model
Merck's multi-segment footprint across pharmaceuticals, life‑science tools and performance materials provides diversified revenue streams and reduces dependence on any single product cycle. That structural diversity supports steadier cash flows and resilience across economic or industry-specific downturns over the next several months.
Negative Factors
Recent top-line weakness
Revenue declined in 2025 after a 2024 rebound, reflected in a negative revenue growth metric. Prolonged or recurring top‑line weakness can reduce operating leverage, constrain reinvestment and slow pipeline commercialization, making it harder to sustain prior growth rates over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
Merck's multi-segment footprint across pharmaceuticals, life‑science tools and performance materials provides diversified revenue streams and reduces dependence on any single product cycle. That structural diversity supports steadier cash flows and resilience across economic or industry-specific downturns over the next several months.
Read all positive factors
Merck KGaA (MRK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€48.63B
Dividend Yield1.82%
Average Volume (3M)321.00K
Price to Earnings (P/E)20.4
Beta (1Y)0.93
Revenue Growth1.47%
EPS Growth9.64%
CountryDE
Employees59,020
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.88
Shares Outstanding129,242,250
10 Day Avg. Volume344,164
30 Day Avg. Volume321,004
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€138.86Price Target Upside22.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)7.72
Revenue Forecast (FY)€20.89B
Merck KGaA Business Overview & Revenue Model
Company Description
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and p...
How the Company Makes Money
Merck KGaA generates revenue through multiple streams including the sale of pharmaceuticals and biopharmaceuticals, which represent a significant portion of its income. The healthcare segment focuses on innovative medicines and biosimilars, while ...
Merck KGaA Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.10B | 21.16B | 20.99B | 22.23B | 19.69B |
| Gross Profit | 11.89B | 11.95B | 11.67B | 12.84B | 11.60B |
| EBITDA | 5.95B | 6.17B | 5.83B | 6.79B | 5.99B |
| Net Income | 2.61B | 2.78B | 2.82B | 3.33B | 3.06B |
Balance Sheet | |||||
| Total Assets | 52.10B | 51.57B | 48.49B | 48.53B | 45.36B |
| Cash, Cash Equivalents and Short-Term Investments | 2.74B | 2.71B | 2.41B | 1.64B | 1.62B |
| Total Debt | 11.97B | 10.27B | 9.94B | 10.40B | 10.77B |
| Total Liabilities | 23.44B | 21.58B | 21.74B | 22.52B | 23.95B |
| Stockholders Equity | 28.59B | 29.91B | 26.68B | 25.93B | 21.34B |
Cash Flow | |||||
| Free Cash Flow | 2.35B | 2.40B | 1.76B | 2.45B | 3.19B |
| Operating Cash Flow | 3.93B | 4.59B | 3.78B | 4.26B | 4.62B |
| Investing Cash Flow | -4.26B | -3.05B | -1.89B | -2.74B | -1.58B |
| Financing Cash Flow | 628.00M | -985.00M | -1.73B | -1.55B | -2.50B |
Merck KGaA Technical Analysis
Neutral
113.00
Price Trends
116.95
Negative
119.12
Negative
115.30
Negative
Market Momentum
-1.55
Negative
51.11
Neutral
77.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MRK, the sentiment is Neutral. The current price of 113 is above the 20-day moving average (MA) of 107.98, below the 50-day MA of 116.95, and below the 200-day MA of 115.30, indicating a neutral trend. The MACD of -1.55 indicates Negative momentum. The RSI at 51.11 is Neutral, neither overbought nor oversold. The STOCH value of 77.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:MRK.
Merck KGaA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €2.37B | 14.36 | 20.45% | 2.34% | 0.11% | 28.09% | |
58 Neutral | €48.63B | 20.44 | 9.02% | 1.82% | 1.47% | 9.64% | |
57 Neutral | €42.14B | 27.87 | 11.65% | 2.13% | 4.53% | 10.12% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €24.92B | 21.83 | 6.70% | 2.05% | 0.63% | ― | |
50 Neutral | €13.24B | 110.19 | 5.77% | 0.39% | 5.82% | 59.90% | |
42 Neutral | €804.65M | 16.56 | -12.28% | ― | -2.67% | 7.40% |
* General Sector Average
DE:MRK
Merck KGaA
113.00
-3.79
-3.24%
DE:EVT
Evotec
4.70
-1.24
-20.93%
DE:FRE
Fresenius SE & Co. KGaA
44.49
6.28
16.43%
DE:SRT
Sartorius
171.40
10.70
6.66%
DE:DMP
Dermapharm Holding SE
45.00
8.33
22.70%
DE:SHL
Siemens Healthineers AG
37.79
-5.99
-13.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.